Affiliation: | aGraduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya 467-8603, Japan bCREST, Japan Science and Technology Agency, 4-1-8 Honcho, Kawaguchi 332-0012, Japan cInstitute of Biological Chemistry, Academia Sinica, 128, Academia Road, Section 2, Nankang, Taipei 115, Taiwan dDepartment of Biomedical Sciences, College of Life and Health Sciences, Chubu University, 1200 Matsumoto-cho, Kasugai 487-8501, Japan eInstitute of Bioengineering, Zhejiang Academy of Medical Sciences, 182 Tianmushan Road, Hangzhou 310013, China fGLYENCE Co., Ltd, 2-22-8 Chikusa, Chikusa-ku, Nagoya 464-0858, Japan gThe Glycoscience Institute, Ochanomizu University, 2-1-1 Ohtsuka, Bunkyo-ku, Tokyo 112-8610, Japan hDepartment of Biochemistry, University of Shizuoka, School of Pharmaceutical Sciences, Shizuoka Yada, Shizuoka 422-8526, Japan iCombi Corporation, Functional Foods Division, 5-2-39 Nishibori, Sakura-ku, Saitama 338-0832, Japan jGlobal COE Program for Innovation in Human Health Sciences, Yada, Shizuoka 422-8526, Japan kInstitute for Molecular Science, National Institutes of Natural Sciences, 5-1 Higashiyama Myodaiji, Okazaki 444-8787, Japan |
Abstract: | Edible bird’s nest (EBN) is the nest made from the saliva of Collocalia swift. Recently, we have found that EBN extract could strongly inhibit infection of influenza viruses in a host-range-independent manner [Guo, C. T.; Takahashi, T.; Bukawa, W.; Takahashi, N.; Yagi, H.; Kato, K.; Hidari, K. I.; Miyamoto, D.; Suzuki, T.; Suzuki, Y. Antiviral Res. 2006, 70, 140–146]. Although this antiviral activity might be attributed to O- or N-glycoconjugates, no N-glycan structures have so far been described for EBN. Here, we report the N-glycosylation profile of EBN, in which a tri-antennary N-glycan bearing the 2,3-N-acetylneuraminic acid residues is displayed as a major component. We suggest that the sialylated high-antennary N-glycans of EBN contribute to the inhibition of influenza viral infection. |